Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) - Trial NCT06285240
Access comprehensive clinical trial information for NCT06285240 through Pure Global AI's free database. This Phase 1 trial is sponsored by Merck Sharp & Dohme LLC and is currently Not yet recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Merck Sharp & Dohme LLC
Timeline & Enrollment
Phase 1
Mar 15, 2024
Jul 25, 2024
Primary Outcome
Number of participants experiencing an Adverse Event (AE),Number of participants discontinuing study treatment due to an AE
Summary
The main purpose of this study is to assess the safety and efficacy of MK-1167 administered
 to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06285240
Non-Device Trial